Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab vs Docetaxel in Previously Treated NSCLC (KEYNOTE-010)
NCT01905657Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2013
- Primary completion
- Sep 2015
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Aug 2013; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01905657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01905657.